Technological projects portfolio

CYCLOPE

Fighting +ssRNA viruses

Investment: €603k

Scope: Healthcare

Scientific field(s): Biology and medicinal chemistry

Institution(s): CNRS - Inserm - Institut de recherche pour le développement - Université de la Réunion - Université Paris-Saclay

Development: Technology to be marketed

#Antiviral #NewChemicalEntity #+ssRNAVirus

USE CASES

Zoonotic viruses with a positive-sense, single-stranded genome made of RNA, such as the dengue virus (DENV), yellow fever virus, Japanese encephalitis virus (JEV), West Nile, Zika virus (ZIKV), chikungunya virus (CHIKV) and Ross River virus (RRV), as well as the coronaviruses, including SARS-CoV-2 which is responsible for COVID-19, are the cause of major epidemics with potentially significant mortality rates for humans.

Vector-borne viral infections (arboviruses) that are fatal for humans, such as dengue, which is a global priority, concern billions of individuals across the world. Coronavirus infections from wild fauna such as SARS-CoV-2 have become a new priority in public health over the past twenty years.

To contain the emergence and/or propagation of viral infectious diseases, it is essential that we quickly have access to antiviral molecules that can act as therapeutic agents.

ADVANTAGES

The Cyclope technology is based on the extraction of a new compound taken from screening natural molecules from plants that present strong antiviral activity.

This new molecule demonstrates low cellular toxicity and high antiviral activity on positive-sense, single-stranded RNA viruses. Its potential target has been identified.

APPLICATIONS

The product developed by Cyclope positions itself on the market of antivirals to combat emerging viruses of medical interest, by developing a new large spectrum molecule against the chikungunya, dengue, Zika, Ross River, and SARS-CoV-2 viruses.